CF Organization of Care in the Era of Highly Effective Modulator.

Recruiting Observational Study
Cystic Fibrosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
6 and older
Sex
Any
Study type
Observational
Participants needed
5,000 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Recently, triple therapy has made it possible to extend access to these modulators to a large proportion of the patient population, with spectacular clinical benefits, provided the patient carries at least one F508del mutation. The hypothesis is that the arrival of CFTRmHEs has considerably altered the way cystic fibrosis is managed, requiring a rethink of how the CRCMs are organised, and a redef…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients aged 6 and over with cystic fibrosis treated with CFTRmHE for at least 12 months * Patients aged over 6 years with cystic fibrosis not eligible for CFTRmHE treatment * Families of patients under 18 years of age * Professionals working in a CRCM for more than 12 months…
Contacts

Philippe REIX, Professor

04 27 85 50 42

philippe.reix@chu-lyon.fr

CONTACT

Julie HAESEBAERT, Professor

04 72 11 57 05

julie.haesebaert@chu-lyon.fr

CONTACT